EGFR mutant-specific inhibitor ZN-e4

{
  "id": "MLC-T-ONC-013267",
  "term": "EGFR mutant-specific inhibitor ZN-e4",
  "field": "Oncology and biomedicine",
  "definition": "An orally available selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutation T790M, with potential antineoplastic activity. Upon administration, the EGFR mutant-specific inhibitor ZN-e4 specifically binds to and inhibits selective EGFR mutations, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to other EGFR inhibitors, ZN-e4 may offer therapeutic benefits in tumors with T790M-mediated drug resistance and may limit toxicities associated with non-selective EGFR inhibitors. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/egfr-mutant-specific-inhibitor-zn-e4/"
}